Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: General and other
Stage/Subtype:  brain stem glioma, adult
Country:  U.S.A.
Trial Type:  Treatment
Results 1-16 of 16 for your search:
Start Over
Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG221-C-003, NCI-2015-01170, NCT02273739
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: ONC-02019-L, NCI-2013-00781, eIRB #922, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Nilotinib in Treating Patients with Recurrent Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 091728, NCI-2010-01839, NCT01140568
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Dexanabinol in Treating Patients With Recurrent Brain Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SK01-ETS2101, NCI-2012-01204, 111827, NCT01654497
Activated Natural Killer Cells with or without Recombinant Interleukin-15 in Treating Younger Patients with Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 25
Trial IDs: 13-C-0152, NCI-2013-01215, 09-25-0099, 130152, P9493_A06PAMDREVW01, 9493, NCT01875601
Viral Therapy before and during Surgery and Flucytosine after Surgery in Treating Patients with Recurrent High-Grade Glioma
Phase: Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: Tg 511-13-01, NCI-2014-02478, TOG1314, NCT01985256
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG120-C-002, NCI-2014-00868, NCT02073994
Temozolomide and Ascorbic Acid in Treating Patients with Recurrent High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 735-13, NCI-2014-01061, NCT02168270
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients with Recurrent High Grade Gliomas
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.528, NCI-2014-01344, 2013-12, 3007, NCT02186509
Genetically Modified T-cells in Treating Patients with Recurrent or Refractory Malignant Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 13384, NCI-2014-01488, 117388, 118810, NCT02208362
Pembrolizumab with Hypofractionated Stereotactic Irradiation and Bevacizumab in Treating Patients with Recurrent High-Grade Gliomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17978, NCI-2015-00751, 14.12.0008, Merck IISP 51561, NCT02313272
Imiquimod and Vaccine Therapy in Treating Younger Patients with Recurrent or Progressive Glioblastoma Multiforme or Diffuse Intrinsic Pontine Glioma
Phase: No phase specified
Type: Treatment
Age: 3 and over
Trial IDs: 2009LS136, NCI-2012-00322, NCT01400672
Conditioning Therapy Followed by Stem Cell Transplant in Treating Patients with High Risk or Relapsed Solid or Central Nervous System Tumors
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: 2011OC057, NCI-2013-02265, 1107M02641, MT2011-09C, NCT01505569
Start Over